Qualification of Digital Endpoints of Function in Healthy Volunteers for Use in a Decentralized Natural History Study in Genetic Parkinson’s Disease (PD)
Objective: Our goal was to qualify digital and wearable devices to assess the Timed Up and Go (TUG) test and gait related parameters in healthy…Expectations of DBS: the patient’s perspective
Objective: To examine the evolution and change of the treatment-related expectations of patients with advanced Parkinson’s Disease (PD) before and during treatment with bilateral deep…Neuroprotective effects of estradiol and progesterone in brain of different age groups of naturally menopausal rats.: A therapeutic potential drug for Parkinson’s disease
Objective: The objective of this study was to determine the effect of E2 and P4 on the activity of acetylcholinesterase (AChE) and monoamine oxidase (MAO), oxidative stress…Dopamine agonist utilization prior to the initiation of device aided therapy: data from 150 patients with advanced Parkinson’s disease treated with Levodopa Carbidopa Intestinal Gel
Objective: Objective: To evaluate the usage of dopamine agonists (DA) as part of the last conventional dopaminergic treatment in a large cohort of consecutive patients…Influence of alcohol consumption on cognitive decline in Parkinson disease.
Objective: To assess whether alcohol consumption (AC) is independently associated with cognitive decline (CD) in PD. Background: AC is linked to dementia and neurological damage…DIFFERENT PATTERNS OF ACUTE SACCADIC RESPONSES TO LEVODOPA CHALLENGE TEST IN DE NOVO PARKINSON’S DISEASE: POSSIBILE PROGNOSTIC IMPLICATIONS
Objective: To explore possible different patterns of acute saccadic responses to Levodopa Challenge Test (LCT) in a de novo drug-naïve Parkinson’s Disease (PD) population and…Spectral somatotopy of the human subthalamic nucleus in Parkinson’s disease
Objective: This study aims to systematically investigate the spatial segregation of a wide range of spectral features of local field potentials (LFPs) within the STN…Investigating the use of DAT-SPECT as an enrichment biomarker to determine eligibility for the phase 2 clinical trial PASADENA
Objective: Evaluate dopaminergic imaging DAT-SPECT as an enrichment strategy to avoid inclusion of participants with scans without evidence of dopaminergic deficit (SWEDD) in a Phase…Reported Clinical and Quality-of-Life Outcomes With 24-Hour Levodopa-Carbidopa Intestinal Gel Administration Compared With 16-Hour Administration
Objective: To evaluate any existing differences between the reported outcomes in patients with advanced Parkinson’s disease (APD) using continuous 16-hour (hr) infusions of levodopa-carbidopa intestinal…GLA-associated early-onset Parkinson’s disease: the mimicry between Fabry disease and parkinsonisms
Objective: To characterize an early-onset Parkinson’s disease (EOPD) patient with atypical clinical phenotype. Background: Genome sequencing is allowing new Parkinsonian Syndromes (PS)-associated genes identification. However,…
- « Previous Page
- 1
- …
- 620
- 621
- 622
- 623
- 624
- …
- 1734
- Next Page »